Abstract：Objective: To investigate the efficacy and safety of linezolid and vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Methods: 60 patients with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia were enrolled from January 2016 to March 2017 were randomly divided into two groups according to the random number table. The patients in the control group were treated with vancomycin, The patients in the experimental group were treated with linezolid, and the overall treatment efficiency, the white blood cell concentration before treatment and the concentration of C-reactive protein and the incidence of adverse reactions were compared between the two groups. Results: Compared with the control group, the total effective rate of the experimental group was significantly higher than that of the control group (P <0.01). After treatment, WBC and CRP were significantly lower than those before treatment, the difference was significant, and there was no significant difference between the two groups before and after treatment.WBC and CRP were significantly lower than those in the control group (P <0.05). There was no significant difference in the adverse reaction rate between the experimental group and the control group, (P>|0.05), while the experimental group of patients mainly diarrhea, nausea and other gastrointestinal adverse reactions, the control group of patients mainly to skin reactions, renal dysfunction adverse reactions. Conclusion: The efficacy of linezolid in the treatment of MRSA pneumonia is lower than that of vancomycin, and it is better to control inflammatory response, and the total effective rate of treatment is higher. The treatment of linezolid is mainly caused by diarrhea, nausea and so on. Gastrointestinal adverse reactions, and vancomycin treatment of patients mainly to skin reactions, renal dysfunction adverse reactions, two groups of less adverse reactions, higher safety, worthy of clinical promotion, with reference.
高永民. 利奈唑胺万古霉素治疗耐甲氧西林金黄色葡萄球菌感染的疗效及安全性分析[J]. 河北医学, 2017, 23(9): 1448-1451.
GAO Yongmin. The Effect and Safety of Linezolid and Vancomycin on Methicillin-resistant Staphylococcus Aureus Infection. 河北医学, 2017, 23(9): 1448-1451.
[1] 林志青,黄延玲.利奈唑胺和万古霉素治疗耐甲氧西林金黄色葡萄球菌感染疗效的Meta分析[J].中华传染病杂志,2011,39(6):361~365. [2] 郭伟.重症监护病房中利奈唑胺耐药的金黄色葡萄球菌感染的暴发流行[J].中华结核和呼吸杂志,2011,34(2):103. [3] Hiroaki Takada,Toru Hifumi,Naoki Nishimoto,et al. Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant staphylococcus aureus in the elderly: a retrospective cohort analysis[J].American Journal of Emergency Medicine,2016, 35(2):245~248. [4] 朱林.利奈唑胺治疗老年人院内耐甲氧西林金黄色葡萄球菌感染的效果分析[J].中国当代医药,2013,20(32):94~95. [5] 葛均波,徐永健,主编.内科学[M].第8版.北京.人民卫生出版社,2013:297~368. [6] Equils Ozlem,da Costa Christopher,Wible Michele,et al. The effect of diabetes mellitus on outcomes of patients with nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus: data from a prospective double-blind clinical trial comparing treatment with linezolid versus vancomycin[J].BMC infectious diseases,2016,16: 476. [7] Caffrey AR,Quilliam BJ,Laplante KL,et al.利奈唑胺和万古霉素治疗甲氧西林耐药金黄色葡萄球菌感染的疗效比较[J].中国感染与化疗杂志,2011,11(4):255. [8] An MM 吴娜(译).利奈唑胺和万古霉素治疗耐甲氧西林金黄色葡萄球菌感染的比较:随机对照试验的荟萃分析[J].中国医药工业杂志,2013,44(10):1053. [9] Laura A,Puzniak,Kimbal D,et al.The prevalence of methicillin-resistant staphylococcus aureus colonization in patients with complicated skin and skin structure infections after treatment with linezolid or vancomycin[J].Advances in Infectious Diseases,2014,04(04): 186~193. [10] 徐丹,吴春荣,崔宇慧.利奈唑胺对耐甲氧西林葡萄球菌感染患者降钙素原水平的影响[J].中国生化药物杂志,2016,36(11):88~90. [11] 秦红梅.利奈唑胺治疗耐甲氧西林金黄色葡萄球菌感染重症肺炎的疗效观察[J].中国老年学杂志,2014,34(20):5869~5870. [12] Tong ManShan C,Wisniewski Christopher S,et al.Comparison of Linezolid and Vancomycin for methicillin-resistant staphylococcus aureus pneumonia: institutional implications[J].Pharmacotherapy,2016,36(7): 731~739. [13] 李娉,李庆林.利奈唑胺和万古霉素对耐甲氧西林金黄色葡萄球菌感染疗效的Meta分析[J].安徽医药,2015,19(5):969~973. [14] 庞昶,朴成浩,林树无.利奈唑胺治疗耐甲氧西林金黄色葡萄球菌感染肺炎并发肝功能损伤的危险因素分析[J].医药导报,2015,34(1):43~46. [15] 范大平,张一梅,尚建欣.利奈唑胺治疗耐甲氧西林金黄色葡萄球菌感染的疗效及安全性分析[J].临床肺科杂志,2011,16(10):1520~1521. [16] Alaniz Cesar,Pogue Jason M. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial[J].The Annals of Pharmacotherapy,2012,46(10): 1432~1435. [17] 薛晓燕,周曙俊,王大明.治疗耐甲氧西林金黄色葡萄球菌感染的5种抗菌药物的应用评价[J].药学与临床研究,2015,23(5):497~500.
2017, Vol. 23 
冀公网安备13080202000677号